Brief: PharmAust Receives Orphan Drug Designation From US FDA For Monepantel
17/05/2024 02:27
May 17 (Reuters) - PharmAust Ltd PAA.AX :
* RECEIVED ORPHAN DRUG DESIGNATION FROM US FDA FOR
MONEPANTEL &
ITS TREATMENT OF MOTOR NEURONE DISEASE / AMYOTROPHIC LATERAL
SCLEROSIS
Further company coverage: PAA.AX
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon Therapeutics jumps on deal with US firm
Brief: Neurizon Therapeutics Executes Long-Term Supply Agreement With Elanco
Brief: Neurizon Therapeutics Receives Ethics Approval For Phase 1 Nuz-001 Oral Liquid Formulation Study
Brief: Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 Million
Brief: Neurizon Therapeutics Says Michael Thurn Resigns As Managing Director And CEO